• The Diagnostics & Lab Testing Business Brief — Monday, November 16, 2026
    Nov 16 2026

    The Diagnostics & Lab Testing Business Brief — Monday, November 16, 2026

    • Roche Diagnostics makes its Endotrophin (ETP) research prototype assay available on cobas e801 analyzers at Nordic Bioscience's CLIA laboratory — the second biomarker from the Roche–Nordic collaboration to reach the platform, following the CE-marked Elecsys PRO-C3. (PR Newswire)
    • Alamar Biosciences' NULISA precision proteomics platform features in 46 presentations at CTAD 2026 in Boston, including data showing brain-derived p-tau217 had the strongest association with amyloid and tau accumulation and cognitive progression among 328 plasma proteins in the A4 and LEARN studies. (GlobeNewswire)
    • Arkansas Children's Hospital laboratory develops and validates a molecular measles assay that distinguishes disease-causing from vaccine strains of the virus, presented at the AMP annual meeting in Seattle. (GenomeWeb)
    • Biovica receives a second work order, valued at approximately $150,000, under its expanded master services agreement with a leading global pharmaceutical company for DiviTum TKa testing in an oncology program, to be run at its CLIA-certified San Diego laboratory. (ACCESS Newswire)
    Show More Show Less
    8 mins
  • The Diagnostics & Lab Testing Business Brief — Sunday, November 15, 2026
    Nov 15 2026

    The Diagnostics & Lab Testing Business Brief — Sunday, November 15, 2026

    • VedaBio presents proof-of-concept data at AMP 2026 showing under-10-minute sample-to-answer molecular detection with its target amplification-free CRISPR technology, using a five-result respiratory panel prototype with automated nucleic acid extraction. (Business Wire)
    • NeuroKaire showcases its BrightKaire platform at HLTH 2026: from a standard blood draw, patient-specific functional neurons are generated and antidepressants ranked, with company-reported AUC of 0.81 and 84% positive predictive value. (GlobeNewswire)
    • Feminai, developer of a wearable sensor patch using AI to monitor breast tissue changes for at-home breast cancer screening, captured the $350,000 MedTech Innovator Early-Stage Grand Prize, as ASPS announced its Plastic Surgery Track startups won a combined $355,000. (GlobeNewswire)
    Show More Show Less
    7 mins
  • The Diagnostics & Lab Testing Business Brief — Saturday, November 14, 2026
    Nov 14 2026

    The Diagnostics & Lab Testing Business Brief — Saturday, November 14, 2026

    • Molecular Designs earns its first FDA 510(k) clearance (K262789) for the SimplicityDx Panel FluA/FluB/RSV, a multiplex RT-PCR test for anterior nasal swabs for use in CLIA high-complexity laboratories, with a breakaway format designed to reduce waste. (PR Newswire)
    • Cerenome reports its first quarter of CNSide diagnostic revenue: $0.7 million net on about $1.55 million in gross billings, contracted coverage representing about 190 million covered lives, and an Aetna agreement effective November 1 covering both tumor cell enumeration and molecular profiling. (GlobeNewswire)
    • Owlet Q3 2026: revenue of $30.4 million, subscription revenue of $3.6 million with more than 142,000 Owlet360 paying subscribers, and net income of $1.4 million; the company initiated a camera cable guard safety update and withdrew its full-year 2026 outlook. (Business Wire)
    • A JAMA study led by WashU Medicine finds the blood tau fragment eMTBR-tau243 elevated in advanced chronic traumatic encephalopathy as well as Alzheimer's disease; the measurement technology is licensed to C2N Diagnostics, and the marker has not been validated for diagnosing CTE. (WashU Medicine)
    • VolitionRx Q3 2026: revenue of about $1.6 million, up 157% year over year, operating loss narrowed to $3.3 million, and its French reimbursement submission for the Nu.Q lung cancer test expected this quarter. (PR Newswire)
    Show More Show Less
    7 mins
  • The Diagnostics & Lab Testing Business Brief — Friday, November 13, 2026
    Nov 13 2026

    The Diagnostics & Lab Testing Business Brief — Friday, November 13, 2026

    • CMS finalizes moving stand-alone algorithmic analyses performed on laboratory tests off the Clinical Laboratory Fee Schedule for CY2027, paying them as “other diagnostic tests” under OPPS at New Technology APC rates aligned with CY2026 CLFS rates — a classification change raising industry concerns and uncertainty. (GenomeWeb; CMS)
    • Lucid Diagnostics Q3 2026: 2,871 EsoGuard tests performed and $1.2 million in revenue, a record 1,800+ tests in October after first Medicare payments at $1,938.01 per test, and a $15 million financing closed after the quarter. (PR Newswire)
    • PAVmed update: Veris Health achieves design freeze for its implantable physiological monitor and begins a 90-day GLP animal study, on track for an early 2027 FDA 510(k) submission. (PR Newswire)
    • Naitive receives FDA 510(k) clearance for OsteoSight Spine, extending AI-enabled opportunistic bone mineral density assessment to routine lumbar spine, thoracic spine, and chest X-rays in patients 50 and older. (Orthopedics This Week)
    • Bluejay Diagnostics completes SYMON-II enrollment with 777 evaluable patients for its Symphony IL-6 sepsis test and targets an FDA 510(k) submission in the first half of 2027; the test is not yet FDA cleared or approved. (ACCESS Newswire)
    • Proto360 Health integrates Phenomix Sciences' MyPhenome genetic obesity test into its employer metabolic care program, making it part of the diagnostic assessment before a GLP-1 prescribing decision. (PR Newswire)
    • BCAL Diagnostics (18.46% shareholder) applies to Australia's Takeovers Panel over Genetic Signatures' proposed Microba merger, under which Microba shareholders would own 60% of the combined group; the Panel has made no decision. (TipRanks)
    Show More Show Less
    7 mins
  • The Diagnostics & Lab Testing Business Brief — Thursday, November 12, 2026
    Nov 12 2026

    The Diagnostics & Lab Testing Business Brief — Thursday, November 12, 2026

    • American Cancer Society updates its prostate cancer screening guideline: direct recommendation for PSA-based screening every two years for average-risk men aged 50–69, and annual screening from age 45 for Black men and men with a strong family history. (PR Newswire)
    • Profusa reports progress toward closing its option to acquire G3 Vision Labs: G3's audited FY2025 revenue was $108 million with $5.0 million Adjusted EBITDA; closing is targeted by year-end, and the combined company is expected to operate as a public diagnostics company. (GlobeNewswire)
    • Cleveland Diagnostics' IsoPSA® prostate cancer test is added to the VA Federal Supply Schedule, making it available to roughly 17 million living veterans, more than 9 million of whom actively seek care at VA facilities. (Business Wire)
    • Danaher's Cepheid plans to lay off 67 people in Sunnyvale, California, mostly scientists and engineers, by December 28, according to a WARN notice filed with the state. (MedTech Dive)
    • SciBase Q3 2026: net sales rose 41% and U.S. skin cancer sales rose 68%; the company submitted a 510(k) seeking to expand Nevisense's U.S. indication to non-melanoma skin cancers, expanded its Castle Biosciences collaboration, and secured first U.S. payer coverage after the quarter. (PR Newswire)
    • Metropolis Healthcare plans to add 1,000 collection centres in 12–18 months, building on close to 5,200 centres and more than 200 labs; September-quarter profit rose 43% on revenue up 16%. (Informist)
    Show More Show Less
    7 mins
  • The Diagnostics & Lab Testing Business Brief — Wednesday, November 11, 2026
    Nov 11 2026

    The Diagnostics & Lab Testing Business Brief — Wednesday, November 11, 2026

    • Waters receives FDA 510(k) clearance for the BD OneFlow™ LST and BD OneFlow™ B-CLPD T1 ready-to-use flow cytometry tests for identifying B-cell non-Hodgkin lymphoma, including CLL (96.3% sensitivity / 98.2% specificity for CLL); U.S. commercial availability planned for spring 2027. (PR Newswire)
    • bioMérieux receives FDA 510(k) clearance and EU IVDR CE marking for VITEK® PRO, its automated microbial identification and antimicrobial susceptibility testing system for medium- and high-volume labs; it will replace VITEK 2 and VITEK XL, with commercial launch beginning Q1 2027. (Clinical Lab Products)
    • Mercy BioAnalytics is selected to participate in STRIDE-RCT, the NHS multicancer blood test trial led by the University of Birmingham, expected to involve more than 20,000 patients across at least 200 GP practices in England. (PR Newswire)
    • UW Medicine becomes the first U.S. academic laboratory to bring Roche Diagnostics' cobas® Mass Spec solution into clinical use, beginning patient testing on November 2, 2026 with vitamin and hormone testing. (UW Medicine Newsroom)
    • FDA finalizes guidance on validating in vitro diagnostic tests for emerging pathogens during a declared public health emergency, setting expectations for EUA submissions for lab, point-of-care, and home tests. (Clinical Lab Products)
    • Biozen presents BP2000 data at AHA Scientific Sessions 2026: the next generation of its FDA-cleared BP1000 fingertip system cut average measurement time by 40% in a prospective 85-participant study; BP2000 is investigational. (PR Newswire)
    Show More Show Less
    8 mins
  • The Diagnostics & Lab Testing Business Brief — Tuesday, November 10, 2026
    Nov 10 2026

    The Diagnostics & Lab Testing Business Brief — Tuesday, November 10, 2026

    • FDA approves Promega's OncoMate® MSI Dx Analysis System as a companion diagnostic to identify patients with MSI-High solid tumors for treatment with KEYTRUDA® (pembrolizumab); the PCR-based assay was developed in collaboration with Merck. (Business Wire)
    • Cepheid achieves CE marking under the EU IVDR for the Xpert® Respiratory Panel, a multiplex PCR test detecting 13 respiratory pathogens from a single nasopharyngeal swab on GeneXpert systems; shipments to CE-mark countries begin in the coming weeks. (PR Newswire)
    • C2N Diagnostics partners with LSI Medience to pursue regulatory approval and commercialization in Japan of the PrecivityAD2® Alzheimer's blood test, which is FDA cleared in the U.S. for adults 40+ with cognitive impairment. (Business Wire)
    • OraSure Technologies Q3 2026: total revenue $30.9M (+14% YoY), Diagnostics $16.8M (+16%), gross margin 45.2%, net loss $13.1M, cash $148M; first orders for Colli-Pee®•Dx and OraQuick® Ebola 2.0; Q4 guidance $30.0–$32.0M. (GlobeNewswire)
    • Cordio Medical's HearO smartphone voice-analysis system predicted over 70% of heart failure events an average of 24.6 days in advance in the 563-patient DETECT-HF pivotal study presented at AHA 2026; the company will pursue FDA De Novo authorization ahead of a planned 2027 U.S. launch. (PR Newswire)
    • Charles River Laboratories to acquire Frontage Holdings' bioanalysis and DMPK operations in Exton, Pennsylvania for approximately $470M in cash plus up to $75M in performance-based payments; close expected in the first half of 2027. (Business Wire)
    Show More Show Less
    7 mins
  • The Diagnostics & Lab Testing Business Brief — Monday, November 9, 2026
    Nov 9 2026

    The Diagnostics & Lab Testing Business Brief — Monday, November 9, 2026

    • Quest Diagnostics pays $13,014,576 plus interest to settle False Claims Act / Anti-Kickback Statute allegations over free New York Giants entertainment for referral sources (2013–2022), plus a five-year Corporate Integrity Agreement; allegations only, no determination of liability. (U.S. Department of Justice)
    • bioMérieux receives FDA 510(k) clearance for the BIOFIRE FILMARRAY Gastrointestinal 1.1 Panel (22 pathogens; also IVDR CE marked) and the GI 1.1 Panel Mid (11 pathogens), with a redesigned norovirus assay and improved Campylobacter detection; results in about one hour. (bioMérieux)
    • Hologen and Sysmex form Saibogen, a joint venture applying generative AI Large Medicine Models to routine hematology data from Sysmex analyzers (~3 billion tests a year); software delivered exclusively through Sysmex analyzers, first offerings research use only. (GlobeNewswire)
    • Photocure updates AssureMDx Medicare timelines: CMS pricing determination expected before year-end 2026 (effective January 1, 2027), but the test was not included in the November 6, 2026 LCD for urine-based biomarkers in microhematuria, so Medicare coverage planning remains 2028. (Photocure)
    • QuidelOrtho's restructuring into Core Diagnostics and Point of Care Diagnostics takes effect November 9, 2026: Q3 revenue $619M (−12%), program targeting over $80M in annual savings in 2027. (QuidelOrtho SEC Form 8-K)
    Show More Show Less
    7 mins